Results 51 to 60 of about 20,787 (190)

Modern basal insulin analogs: An incomplete story

Indian Journal of Endocrinology and Metabolism, 2014
The currently available basal insulin does not completely mimic the endogenous insulin secretion. This has continued to promote the search for ideal basal insulin.
Awadhesh Kumar Singh, Kalyan Kumar Gangopadhyay   +1 more
doaj   +1 more source

Basal insulin titration algorithms in patients with type 2 diabetes: the simplest is the best (?)

Mìžnarodnij Endokrinologìčnij Žurnal, 2023
Basal insulin is the first and main component of insulin therapy in patients with type 2 diabetes mellitus (T2DM). Based on the shortcomings of human NPH insulin and the advantages provi­ded by long-acting basal insulin analogues, they are recommended ...
V.I. Katerenchuk
doaj   +1 more source

Liraglutide for the treatment of type 2 diabetes : a single technology appraisal [PDF]

, 2011
This paper presents a summary of the Evidence Review Group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s submission to the National ...
Cummins, E. (Ewen), Royle, Pamela, Shyangdan, D. (Deepson), Waugh, Norman   +3 more
core  

Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj, Mohammed Zuber, Muhammed Rashid, Manik Chhabra, Krishna Undela, Smita Rawal, Lorenzo Villa Zapata   +6 more
wiley   +1 more source

A Difference Between Bedtime and Pre-Breakfast Plasma Glucose Levels Indicates the Need for Prandial Insulin in Basal Insulin-Treated Type 2 Diabetic Patients with Normal Fasting Glucose

Diabetes, Metabolic Syndrome and Obesity, 2021
Stephan Kress,1 Anja Borck,2 Ariel Zisman,3 Peter Bramlage,4,5 Thorsten Siegmund6 1Diabeteszentrum, Vinzentius-Krankenhaus, Landau, Germany; 2Medical Department, Sanofi, Berlin, Germany; 3The Endocrine Center of Aventura, Aventura, FL, USA; 4Institute ...
Kress S, Borck A, Zisman A, Bramlage P, Siegmund T   +4 more
doaj  

A prospective evaluation of the effectiveness and safety of insulin glargine 100 U/mL (Gla-100) in adults with diabetes mellitus in Poland. The LARE observational study

Clinical Diabetology, 2021
Introduction. Insulin glargine 100 U/ml (Gla-100) is a long-lasting basal insulin analog injected once daily. This real-life study aimed to evaluate the efficacy and safety of Gla-100 in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM ...
Grzegorz Jan Dzida, Tomasz Szczepanik
doaj   +1 more source

Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin [PDF]

, 2011
Aims/hypothesis Several publications suggest an association between certain types of insulin and cancer, but with conflicting results. We investigated whether insulin glargine (A21Gly,B31Arg,B32Arg human insulin) is associated with an increased risk of ...
A Dejgaard, AS Fauci, B. H. Ch. Stricker, BH Stricker, CH Chang, CJ Currie, D Mayer, D Mayer, D Simon, E Friberg, E Giovannucci, E Mannucci, Emerging Risk Factors Collaboration, H. R. Haak, HC Gerstein, HM Colhoun, J Rosenstock, J. W. W. Coebergh, JA Johnson, JM Jonasson, K Rothman, KL Edwards, L. E. Visser, LG Hemkens, LV Poll-Franse van de, M. P. P. van Herk-Sukel, MM Hassan, N Morden, P Kurtzhals, P Vigneri, P. H. Geelhoed-Duijvestijn, PD Home, R Huxley, R. M. C. Herings, R. Ruiter, S Bonovas, S Hernandez-Diaz, S Suissa, S. M. J. M. Straus, SC Larsson, SC Larsson, SC Larsson, SE Kahn, SJ Pocock, SL Bowker, SS Coughlin, U Smith, VA Grote, X Yang, YX Yang   +49 more
core   +5 more sources

Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long‐acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin.
Julia Brillinger, Christopher Filliter, Shahrzad Salmasi, Estefania Zapata‐Bravo, Robert W. Platt, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

Glargine and degludec: solution behaviour of higher dose synthetic insulins [PDF]

, 2017
Single, double and triple doses of the synthetic insulins glargine and degludec currently used in patient therapy are characterised using macromolecular hydrodynamic techniques (dynamic light scattering and analytical ultracentrifugation) in an attempt ...
A Ortega, A Stradner, B Zinman, C Homko, CM Reno, CN Cramer, D Aizen, D Roith Le, DB Steensgaard, DJ Scott, DR Owens, EJ Dodson, G Bentley, I Zib, J Dam, J Rosenstock, KI Birkeland, M Monami, MC Riddle, MJ Adams, P Kurtzhals, P Schuck, PR Wills, R Solomon Zemler, RB Gillis, S Ang, SE Harding, SE Harding, SJ Jacober, T Heise   +29 more
core   +2 more sources

Efficacy and safety of switching basal insulin to insulin glargine 300 U/mL in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo‐Neo T2DM study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This real‐world study evaluated the effectiveness and safety of switching basal insulin (BI) to insulin glargine 300 U/mL (Gla‐300) in adults with inadequately controlled type 2 diabetes mellitus (T2DM), previously receiving basal‐supported oral therapy plus prandial insulin (BOTplus) or multiple (≥3) daily injections (MDI) of short ...
Stefan Pscherer, Andreas Fritsche, Helmut Anderten, Katrin Pegelow, Henry Y. Han, Martin Pfohl, Jochen Seufert   +6 more
wiley   +1 more source